SINOVAC Announces New Board Member

Beijing, China:
Sinovac Biotech Ltd. (Nasdaq: SVA) ('SINOVAC' or the 'Company'), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the 'Board') and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang's resignation was due to increased professional commitments and time constraints and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
The Board has appointed Geoffrey C. Hsu, CFA, as a director to the Board to fill the vacancy created by such resignation under the laws of Antigua and Barbuda. Mr. Hsu has also been elected as a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board.
Mr. Hsu is a General Partner and Portfolio Manager at OrbiMed, one of the world's largest dedicated healthcare investment firms, managing over $17 billion in assets. Mr. Hsu brings extensive investment experience in the biotechnology industry and China. He joined OrbiMed in 2002 and has been a Portfolio Manager since 2005, leading the public equity team's biotech and emerging markets efforts. He has been responsible for overseeing the firm's public equity investments in China since 2009 and the firm's investment in SINOVAC since 2013. Prior to joining OrbiMed, Mr. Hsu worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. He received an A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School.
Following this appointment, the Board consists of four members, including Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven H. Borho, CFA, and Mr. Hsu. The Audit Committee of the Board consists of three members, including Mr. Borho, Mr. Lo and Mr. Hsu. The Compensation Committee and the Corporate Governance and Nominating Committee of the Board each consists of Dr. Li, Mr. Lo and Mr. Hsu.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under 'Category 1 Preventative Biological Products' and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please visit the Company's website at www.sinovac.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617453752/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

New York Post

19 minutes ago

• New York Post

Another buyer has made offer for Rays in potential twist

Another potential Rays buyer has thrown a hat in the ring. Trip Miller, the founder of a Memphis hedge fund, is the latest to join the billionaire race to own the Rays as he created a group that made an all-cash offer to Rays owner Stu Sternberg, according to The Athletic. 'We made an offer last week,' Miller said, per The Athletic. 'We have had contact with the club over the past month, specifically about our offer. 4 Rays' current owner, Stuart Sternberg, answered reporters' questions in March. Kim Klement Neitzel-Imagn Images 'If there is an exclusivity period that expires soon, and I don't know when it expires, we would welcome the opportunity to have a deeper discussion with the Rays about our offer.' It was reported Wednesday that Sternberg was in 'advanced talks' to sell the franchise with a group led by Jacksonville homebuilder Patrick Zalupski having executed a letter of intent to purchase the club. 4 Patrick Zalupski is the founder, chairman and CEO of Dream Finders Homes, a Florida-based homebuilder. University of Florida Zalupski's group's offer was reported to be $1.7 billion, according to Sportico. As for Miller's offer, he did not reveal the number but included that he and his group are willing to raise the number if necessary. The Rays are currently in need of a new stadium as they can't play at Tropicana Field after the stadium sustained damage from Hurricane Milton in October 2024. Tampa Bay has instead played at George M. Steinbrenner Field in Tampa — home to the Yankees' spring training and Low-A team. 4 Tropicana Field was ravaged by Hurricane Milton in October 2024. AFP via Getty Images The stadium issue is something that MLB is hoping a new owner would solve, as Sternberg had a deal in place to begin building a new 30,000-capacity stadium in downtown St. Petersburg before the plans ended because of financing delays. 'The league, that's what they're looking for — someone who can not only buy the club but solves the stadium problem,' Miller said. While finding a new stadium is a priority, relocating out of Central Florida is seemingly not an option. 4 Rays legend Evan Longoria puts on a jersey after signing an honorary one-day contract, alongside current Rays owner Stu Sternberg. AP 'This is not a relocation play to another state,' Miller said. 'You won't see the Rays relocating out of Central Florida, whether it was our group or another group.' Miller said that Orlando is not out of the realm of possibilities for relocation and that, all in all, the total investment for the team and a new stadium will be more than $3 billion.

Yahoo

19 minutes ago

• Yahoo

Why Advanced Micro Devices Stock Moved Higher Today

AMD stock jumped early in today's trading, but it gave up most of its gains as the market focused on risk factors for the tech sector and broader market. Investors are seeing signs that AMD is positioned to rack up wins in the artificial intelligence (AI) processor space. AMD's new AI processor and server products could deliver significant wins, but geopolitical dynamics and other factors could still create volatility for the stock. 10 stocks we like better than Advanced Micro Devices › Advanced Micro Devices (NASDAQ: AMD) stock ended Friday's trading in the green, despite pullbacks following a pop early in the session. The company's share price closed out the day up 1.1%, but it had been up as much as 4.7% earlier in the session. Meanwhile, the S&P 500 (SNPINDEX: ^GSPC) fell 0.2% in the daily session, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) fell 0.5%. Thanks to rising excitement surrounding the company's position in artificial intelligence (AI), AMD stock opened today's trading with a big gain. The company's share price still advanced in the daily session, but it lost some ground as investors weighed new export restrictions for semiconductor technologies and the risk of escalating conflict in the Middle East. AMD stock has seen wild fluctuations over the last couple of years in conjunction with shifting expectations for the company's standing and market opportunity in the AI space. Following the Advancing AI 2025 conference hosted by the hardware specialist last week, market sentiment surrounding the stock has become significantly more bullish. At the conference AMD profiled its recently launched Instinct MI350 graphics processing unit (GPU) and its new server product for data centers. The company also announced that it had entered into a new deal to supply OpenAI with processing hardware, and its indications suggest that it may have also reached a new deal with Amazon. AMD appears to be making some laudable progress in the AI hardware market. While the company may continue to play second fiddle to Nvidia in the high-end data center GPU market, it will likely still have opportunities to score some big wins in the space. On the other hand, AMD stock could see high levels of volatility in the near term. Tech stocks wavered today following news that the Trump administration was implementing new bans on tech exports to China, and the market is also on edge about the possibility that the U.S. could get involved in the conflict between Israel and Iran. So even though AMD's AI growth bets appear to be moving in the right direction, there are other big catalysts that could shape stock performance in the near term. Before you buy stock in Advanced Micro Devices, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Advanced Micro Devices wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Amazon, and Nvidia. The Motley Fool has a disclosure policy. Why Advanced Micro Devices Stock Moved Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo

an hour ago

• Yahoo

These may be the 3 most effective non-drug ways to treat knee arthritis

A knee brace appears to be one of the more effective ways to treat the pain - as well as improve function and stiffness - from osteoarthritis, the common degenerative process where the cartilage cushioning the joint deteriorates over time. Researchers in China ranked the relative effectiveness of a dozen treatments, ranging from laser and ultrasound therapy to wedged insoles and kinesiology tape, studied in 139 randomized controlled trials. Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. Based on the results from 9,644 participants, the simple knee brace ranked highest in effectiveness to alleviate symptoms of arthritis, the researchers concluded. However, 'the challenge,' said Prakash Jayabalan, the director of musculoskeletal research at the Shirley Ryan AbilityLab in Chicago, 'is getting patients to actually wear knee braces.' Jayabalan and other clinicians who weren't involved in the study said knee braces can provide certain people immediate relief by supporting the load on the joint. But, some patients find braces uncomfortable to wear. Hydrotherapy and exercises such as weightlifting and yoga placed second and third in the meta-analysis ranking. Hydrotherapy, also known as water exercises or aquatherapy, is a treatment approach designed to improve symptoms. And experts said staying active and maintaining a healthy weight are the most effective ways to relieve symptoms of knee osteoarthritis. 'Both of those can improve symptoms and slow the progression of arthritis,' said Morgan Jones, a sports medicine orthopedic surgeon at Mass General Brigham. The peer-reviewed study published in PLOS One on Wednesday. It was led by Yuan Luo, a researcher in the department of rehabilitation at the First People's Hospital of Neijiang, China, who did not respond to questions by the time of publication. - - - What causes knee osteoarthritis? When cartilage in the knee breaks down, the joint is left with 'bone on bone motion,' Jayabalan said. Cartilage can't repair itself like other tissues in the body and, oftentimes, people don't know they've lost the cartilage in their knee until it's gone, he said. There are two common risk factors for knee arthritis - a previous knee injury such as an ACL tear and unhealthy weight gain, said Steve Messier, the director of the J.B. Snow Biomechanics Laboratory at Wake Forest University. Every pound of additional body weight amounts to four pounds of stress on the knees when a person is walking, Messier said. Once someone has arthritis in their knee, they need to make broad lifestyle changes with regular exercise to manage the pain, he said. 'It really doesn't matter what type of exercise you do, just so you're being active,' Messier said. 'They all will reduce pain.' Other clinicians agree staying active is one of the best ways to relieve knee arthritis pain. It's the first recommendation in guidelines published in 2019 from the Osteoarthritis Research Society International. Around 33 million U.S. adults have osteoarthritis, according to the Centers for Disease Control and Prevention. People commonly take NSAIDs such as ibuprofen to relieve the symptoms. But, these pain-relievers can damage the lining of your gut. Jayabalan said he recommends people use NSAIDs for no more than 10 days when they're experiencing 'debilitating pain' that is impacting their function. 'You should not be taking these every day,' he said. Knee replacements have long been the gold standard for damaged joints, but it can take up to a year for some people to fully recover from surgery. Emerging alternatives target the nerves to stop the knee pain and block blood flow to reduce inflammation. 'Two people can have the same amount of structural damage in their knee and have totally different pain profiles,' said Jones, also an assistant professor of orthopedic surgery at Harvard Medical School. 'The decision for knee replacement ends up being really individualized, and the focus is on the person's symptoms.' - - - What did the study find? The knee brace ranked best on various scores of pain, stiffness and function, and had the 'highest probability of being the best technique,' the researchers wrote. Jones said a knee brace can be 'very effective' in people who have arthritis in certain compartments of the knee because the brace can shift the load to another part of the joint. 'But, if somebody has arthritis throughout their knee, an unloader brace is not as likely to be helpful,' he said. 'They don't have a more-normal area to off-load the force to.' The researchers compared a dozen interventions: low-level laser therapy, high-intensity laser therapy, transcutaneous electrical nerve stimulation, interferential current, short wave diathermy, ultrasound, lateral wedged insole, knee brace, exercise, hydrotherapy, kinesio taping and extracorporeal shock wave therapy. Hydrotherapy ranked second in some scores. Water buoyancy takes pressure off the knee joints and helps improve range of motion for some people, Jayabalan said. Ultrasound pulse therapy to treat knee arthritis 'remains contentious' and performed the worst across multiple scores, the researchers wrote. And, they concluded that wedged insoles, which attempt to shift the load on the knee by lifting one side of the foot, did not 'outperform neutral devices in pain reduction.' Insoles used to be a popular therapy for knee osteoarthritis but 'multiple studies' have shown they don't help, Jones said. - - - The study's limitations Many of the studies in the meta-analysis are short, six to 12 weeks, Messier said. Therefore, the results support only short-term pain relief from these treatments. 'It may relieve pain for a little while, but it's not going to change pain in the long run,' Messier said. 'The most effective thing they have here is exercise.' Jayabalan said none of the studies are looking at whether the treatments led to mechanistic improvements in the knee - 'they were not regrowing cartilage, or something like that.' Instead, the studies recorded clinical observations that these treatments may provide a potential benefit. And, many of the randomized controlled trials were conducted on small groups of participants, Jones said. 'There's a lot of variability in the studies and how long they follow their patients,' he said. Related Content 3-pound puppy left in trash is rescued, now thriving How to meet street cats around the world 'Jaws' made people fear sharks. 50 years later, can it help save them?